MXPA03000046A - Interleucina-2 estabilizada. - Google Patents
Interleucina-2 estabilizada.Info
- Publication number
- MXPA03000046A MXPA03000046A MXPA03000046A MXPA03000046A MXPA03000046A MX PA03000046 A MXPA03000046 A MX PA03000046A MX PA03000046 A MXPA03000046 A MX PA03000046A MX PA03000046 A MXPA03000046 A MX PA03000046A MX PA03000046 A MXPA03000046 A MX PA03000046A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- stabilized
- variant
- preferred formulation
- reconstitution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Train Traffic Observation, Control, And Security (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Sub-Exchange Stations And Push- Button Telephones (AREA)
Abstract
Se presenta una preparacion farmacéutica estable que comprende interleucina-2 humana o una variante de la misma y una cantidad estabilizadora de histidina. Una formulacion preferida incluye glicina y sucrosa y una variante de IL-2 que tiene una mutacion simple, N88R. La formulacion preferida se encuentra en forma liofilizada la cual, al reconstituirse con un diluyente acuoso, resulta en una solucion que tiene un pH dentro de un rango de aproximadamente 5.0 a 6.5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/605,577 US6689353B1 (en) | 2000-06-28 | 2000-06-28 | Stabilized interleukin 2 |
PCT/US2001/020675 WO2002000243A2 (en) | 2000-06-28 | 2001-06-27 | Stabilized interleukin 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03000046A true MXPA03000046A (es) | 2003-06-19 |
Family
ID=24424265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03000046A MXPA03000046A (es) | 2000-06-28 | 2001-06-27 | Interleucina-2 estabilizada. |
Country Status (24)
Country | Link |
---|---|
US (1) | US6689353B1 (es) |
EP (1) | EP1370280B1 (es) |
JP (3) | JP5522878B2 (es) |
KR (1) | KR100799402B1 (es) |
CN (1) | CN1523997B (es) |
AR (1) | AR029139A1 (es) |
AU (1) | AU2001273063A1 (es) |
BR (1) | BR0112101B1 (es) |
CA (1) | CA2413334C (es) |
CO (1) | CO5290308A1 (es) |
CU (1) | CU23536A3 (es) |
DE (1) | DE60142412D1 (es) |
DO (1) | DOP2001000197A (es) |
EC (1) | ECSP014106A (es) |
ES (1) | ES2344729T3 (es) |
HN (1) | HN2001000139A (es) |
IL (2) | IL153587A0 (es) |
MX (1) | MXPA03000046A (es) |
MY (1) | MY128629A (es) |
PE (1) | PE20020127A1 (es) |
SV (1) | SV2002000512A (es) |
TW (1) | TWI235063B (es) |
UY (1) | UY26805A1 (es) |
WO (1) | WO2002000243A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8531276B2 (en) * | 2000-03-15 | 2013-09-10 | Logitech Europe S.A. | State-based remote control system |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
AU2003268664A1 (en) * | 2002-09-26 | 2004-04-19 | Shionogi And Co., Ltd. | Stabilized protein compositions |
US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
RU2418633C2 (ru) * | 2004-04-08 | 2011-05-20 | Байоматрика, Инк. | Объединение процессов хранения образцов и управление образцами в медико-биологических науках |
KR20070110901A (ko) * | 2005-03-04 | 2007-11-20 | 다이나박스 테크놀로지 코퍼레이션 | 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(iss)을 갖는올리고뉴클레오티드를 포함하는 백신 |
CA2643693A1 (en) * | 2006-03-10 | 2007-09-20 | Dyax Corp. | Formulations for ecallantide |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
MX2009012964A (es) * | 2007-06-01 | 2010-01-14 | Acologix Inc | Formulacion de peptido estable a alta temperatura. |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
WO2010132508A2 (en) * | 2009-05-11 | 2010-11-18 | Biomatrica, Inc. | Compositions and methods for biological sample storage |
EP3345593B1 (de) * | 2009-11-13 | 2023-09-06 | Sanofi-Aventis Deutschland GmbH | Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin |
TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
KR102349549B1 (ko) | 2010-11-12 | 2022-01-11 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
JP6034798B2 (ja) * | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 液体ウイルス製剤 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
TWI608847B (zh) | 2011-08-29 | 2017-12-21 | 賽諾菲阿凡提斯德意志有限公司 | 用於控制糖尿病二型病患血糖的醫藥組合物 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
CN103063829B (zh) * | 2012-12-21 | 2015-01-14 | 杭州茂天赛科技有限公司 | 一种冻存液 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3656215B1 (en) | 2014-06-10 | 2021-08-04 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
KR102589056B1 (ko) | 2015-12-08 | 2023-10-12 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018089420A1 (en) | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
KR20200010354A (ko) | 2017-05-24 | 2020-01-30 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
WO2019185705A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
JP2023507115A (ja) | 2019-12-17 | 2023-02-21 | アムジエン・インコーポレーテツド | 治療における使用のためのデュアルインターロイキン-2/tnf受容体アゴニスト |
WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
AU2021286177A1 (en) | 2020-06-03 | 2022-12-01 | Ascendis Pharma Oncology Division A/S | IL-2 sequences and uses thereof |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
MX2023005458A (es) * | 2020-11-13 | 2023-05-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que comprende una variante de la interleucina humana 2 o un derivado de la misma y uso de la misma. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60215631A (ja) * | 1984-04-09 | 1985-10-29 | Takeda Chem Ind Ltd | インタ−ロイキン−2組成物 |
EP0158487B1 (en) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
JPH0645551B2 (ja) * | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−2組成物 |
JPH0229016A (ja) * | 1989-06-09 | 1990-01-31 | Alpine Electron Inc | イコライザ装置 |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
AU8985898A (en) * | 1997-07-31 | 1999-02-22 | Rhodia Chimie | Cosmetic composition comprising a functionalised polyorganosiloxane |
DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
-
2000
- 2000-06-28 US US09/605,577 patent/US6689353B1/en not_active Expired - Lifetime
-
2001
- 2001-06-14 AR ARP010102841A patent/AR029139A1/es active IP Right Grant
- 2001-06-26 DO DO2001000197A patent/DOP2001000197A/es unknown
- 2001-06-26 MY MYPI20013006A patent/MY128629A/en unknown
- 2001-06-26 CO CO01050546A patent/CO5290308A1/es not_active Application Discontinuation
- 2001-06-27 DE DE60142412T patent/DE60142412D1/de not_active Expired - Lifetime
- 2001-06-27 CN CN018144454A patent/CN1523997B/zh not_active Expired - Fee Related
- 2001-06-27 EC EC2001004106A patent/ECSP014106A/es unknown
- 2001-06-27 IL IL15358701A patent/IL153587A0/xx active IP Right Grant
- 2001-06-27 EP EP01952296A patent/EP1370280B1/en not_active Expired - Lifetime
- 2001-06-27 ES ES01952296T patent/ES2344729T3/es not_active Expired - Lifetime
- 2001-06-27 KR KR1020027017859A patent/KR100799402B1/ko active IP Right Grant
- 2001-06-27 UY UY26805A patent/UY26805A1/es not_active IP Right Cessation
- 2001-06-27 CA CA2413334A patent/CA2413334C/en not_active Expired - Lifetime
- 2001-06-27 WO PCT/US2001/020675 patent/WO2002000243A2/en active Application Filing
- 2001-06-27 BR BRPI0112101A patent/BR0112101B1/pt not_active IP Right Cessation
- 2001-06-27 JP JP2002505024A patent/JP5522878B2/ja not_active Expired - Lifetime
- 2001-06-27 SV SV2001000512A patent/SV2002000512A/es unknown
- 2001-06-27 AU AU2001273063A patent/AU2001273063A1/en not_active Abandoned
- 2001-06-27 MX MXPA03000046A patent/MXPA03000046A/es active IP Right Grant
- 2001-06-28 HN HN2001000139A patent/HN2001000139A/es unknown
- 2001-06-28 PE PE2001000639A patent/PE20020127A1/es not_active Application Discontinuation
- 2001-06-28 TW TW090115670A patent/TWI235063B/zh not_active IP Right Cessation
-
2002
- 2002-12-23 IL IL153587A patent/IL153587A/en unknown
- 2002-12-24 CU CU20020334A patent/CU23536A3/es not_active IP Right Cessation
-
2012
- 2012-06-21 JP JP2012139913A patent/JP2012211166A/ja active Pending
-
2014
- 2014-09-08 JP JP2014182175A patent/JP5989728B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY128629A (en) | Stabilized interleukin 2 | |
NZ512792A (en) | Stable liquid interferon beta formulations | |
AU694229B2 (en) | A pharmaceutical preparation comprising glucagon | |
UA26855C2 (uk) | Фармацевтичhа композиція, яка регулює гематопоез | |
MX9502034A (es) | Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion. | |
IE823046L (en) | Stabilised interferon formulations | |
AU590618B2 (en) | Stable formulation of biologically active proteins for parenteral injection | |
ATE146360T1 (de) | Gonadotropin enthaltende gefriergetrocknete troepfen | |
GR3007107T3 (es) | ||
HUP0100090A2 (hu) | Szájápoló készítmények | |
MY102929A (en) | Aqueous pharmaceutical formulations of piroxicam monohydrate | |
AU1381697A (en) | Method for preparation of active substances from nacre, resulting products, useful in medicinal applications | |
DK0641216T3 (da) | Farmaceutisk præparat indeholdende IL-6 | |
IL87778A (en) | Topical pharmaceutical compositions in the form of a hydrogel containing stabilized therapeutically active proteins and their preparation | |
FI964448A (fi) | Uusi biologisesti aktiivinen peptidi ja sen valmistus | |
JPS6479125A (en) | Antitumor agent | |
ES2073063T3 (es) | Formulaciones galenicas acuosas de eritropoyetina y su uso. | |
WO2000032223A3 (en) | Therapeutic treatment with immunogenic drugs | |
ATE427736T1 (de) | Pharmazeutische zubereitungen zur parenteralen verabreichung enthaltend epothilon | |
TH43906B (th) | อินเทอร์ลูคิน 2 ที่ถูกทำให้เสถียรแล้ว | |
UA39712A (uk) | Композиція для очних крапель, що містить інтерферон, та очні краплі на її основі | |
MX9707121A (es) | Formulaciones liquidas de gch. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |